Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool April 22, 2011 Sean Williams	Pharma's Most Perilous Pipelines Patent expirations expose weaknesses for these Wall Street darlings.
The Motley Fool January 8, 2010 Brian Orelli	Heartburn Relieved ... for Now AstraZeneca settles its patent dispute with Teva.
The Motley Fool November 2, 2011 Prabhat Sakya	AstraZeneca vs. GlaxoSmithKline If you could only invest in one of these companies, which would it be?
The Motley Fool November 26, 2008 Brian Orelli	Teva and AstraZeneca's Drama Concludes Teva and AstraZeneca settle a lawsuit, but investors are still left in the dark.
The Motley Fool April 30, 2010 Brian Orelli	Living the Blockbuster Model AstraZeneca's top drugs provide top-line growth in the first quarter.
The Motley Fool July 30, 2010 Cliff D'Arcy	Which Is the Better Big Pharma? AstraZeneca is having a good 2010 -- and its shares are enjoying a great run, too. Here's how it compares to GlaxoSmithKline.
The Motley Fool July 27, 2006 Stephen D. Simpson	AstraZeneca Needs a Rest The stock isn't too expensive, but it's no longer a bargain.
The Motley Fool October 27, 2005 Stephen D. Simpson	AstraZeneca Prepares for a Dry Spell A weak late-stage pipeline will make for challenging earnings growth in the coming years. Investors may want to hold out for a better price here.
The Motley Fool August 6, 2011 Sean Williams	10 Large Caps to Rule Them All There's nothing generic about this company. For the inaugural large-cap pick, I think we should revisit pharma's most impervious pipeline, Teva Pharmaceuticals.
The Motley Fool October 30, 2009 Brian Orelli	Of One-Time Gains and Pipelines AstraZeneca's earnings report illustrates the nature of polar opposites with one-time gains and new drugs. One is to be largely ignored, while the other will drive the drugmaker's future.
The Motley Fool February 2, 2006 Stephen D. Simpson	AstraZeneca: Of Patents and Pipelines Losing Toprol-XL would be a blow, but not a fatal one. So what to do with AstraZeneca's stock? It might not be as cheap as Pfizer or Abbott Labs, but if the pipeline works out, it still seems like there's money to be made here.
The Motley Fool December 29, 2009 Brian Orelli	Some Brand-Name Patents: Going, Going, Gone in 2010 Generic drug competition is coming for Lipitor, Plavix, and others.
The Motley Fool February 5, 2007 Billy Fisher	A Fresh Outlook at AstraZeneca Strong performance makes management happy at the European drug giant. As long as the company is able to continue the strong revenue growth from its major contributors, shareholders will be able to enjoy a prosperous 2007.
The Motley Fool February 1, 2008 Brian Lawler	AstraZeneca's Trying to Get Healthier Big pharma AstraZeneca tries to get back on track by reducing costs.
The Motley Fool January 28, 2011 Alan Oscroft	AstraZeneca to Double Buybacks Regulatory setbacks have hit the drug firm's profits, but things look pretty resilient overall.
The Motley Fool April 28, 2005 Stephen D. Simpson	Standby Drugs Sustain AstraZeneca Sales are good now, but what will a weak pipeline mean to investors in a few years?
The Motley Fool January 31, 2008 Brian Orelli	Wyeth Calls Teva's Bluff Wyeth launches a generic version of its own heartburn drug.
The Motley Fool May 21, 2009 Robert Steyer	The AstraZeneca Dilemma Can AstraZeneca produce enough new drugs to offset a series of upcoming patent expirations?
The Motley Fool October 30, 2008 Brian Orelli	What's on Deck for AstraZeneca? The drugmaker increases EPS by cutting costs, but it's the next move that will count the most.
The Motley Fool November 27, 2006 Brian Lawler	Teva and Pfizer Make Up The companies decide to play nice over generic versions of two of Pfizer's drugs.
The Motley Fool December 30, 2008 Brian Orelli	2009's Generic Drugs: Who's at Risk The patent cliff is coming early for some drugmakers.
The Motley Fool April 24, 2007 Brian Lawler	MedImmune Not Immune to Takeovers MedImmune shops itself to AstraZeneca. MedImmune investors appear to be getting a pretty sweet deal.
The Motley Fool April 26, 2007 Brian Lawler	AstraZeneca's Announcement Overshadows Earnings AstraZeneca releases first-quarter financial results. Investors, take note.
The Motley Fool July 25, 2008 Brian Orelli	Generic Heartburn at Wyeth Revenue from its heartburn drug Protonix dropped 59% year over year after Teva Pharmaceuticals and Sun Pharmaceuticals launched their generic versions of the drug.
The Motley Fool October 26, 2006 Brian Lawler	Market Rejects AstraZeneca's Remedy Investors pummel the pharmaceutical firm, despite its impressive results.
The Motley Fool August 3, 2006 S.J. Caplan	AstraZeneca's Path to Avoid Pain The pharmaceutical giant partners with Pozen to co-develop a drug. Take heart, AstraZeneca shareholders! No queasy stomachs are expected in your future.
The Motley Fool April 25, 2011 Sean Williams	Pharma's Most Impervious Pipeline An investment in generics doesn't have to be a bad thing.
Chemistry World April 24, 2007 Victoria Gill	AstraZeneca Scoops up $15.6 Billion Vaccine Business AstraZeneca has joined the race to scoop up acquisition opportunities in the biologics sector with a $15.6 billion deal to buy U.S. vaccines and biotechnology company MedImmune.
The Motley Fool July 30, 2007 Brian Lawler	AstraZeneca's Yawner of a Quarter The pharma's second-quarter results are ho-hum. Investors may do well to take a look at some of the other big pharma stocks, which offer more compelling reasons to buy.
The Motley Fool October 8, 2007 Brian Orelli	New FDA Regulations for Drugmakers To deal with a growing backlog of pending applications, the FDA plans to stop its first-come, first-served system.
The Motley Fool February 28, 2008 Brian Lawler	Benefiting From 2008's Generic Drugs While drug companies scramble to make up for lost revenue as their products are hit with patent expirations, other companies will benefit from the patent losses. Take a look at some winners and losers of drugs going off patent this year.
The Motley Fool July 30, 2009 Brian Orelli	A Little Help From the Enemy Unfortunately, it won't last. AstraZeneca went over a small patent cliff, but its competitors were nice enough to throw it some climbing gear.
The Motley Fool December 29, 2006 Brian Lawler	Lilly's Patents Stay in Bloom Even with upcoming patent expiries, Lilly isn't in nearly the same desperate situation that some of its large-cap pharma peers will be dealing with in the upcoming years. Investors, take note.
The Motley Fool September 11, 2007 Brian Lawler	Looking Forward at Pfizer With generic competition on the way for Pfizer's top drug, Lipitor, the company stepped up to the podium at the Bear Stearns Healthcare Conference this week to let investors know its plans.
The Motley Fool November 20, 2008 Brian Orelli	Double Trouble for AstraZeneca A double dose of bad news for AstraZeneca. Current revenue is vanishing, and potential revenue is failing to materialize.
The Motley Fool July 14, 2008 Brian Orelli	Teva Gets a Taste of Its Own Medicine Momenta Pharmaceuticals and Novartis are challenging the patents on Teva Pharmaceutical's blockbuster multiple sclerosis drug Copaxone.
The Motley Fool May 17, 2007 Brian Lawler	MedImmune Gets the Thumbs-Up An advisory panel recommends expanded use for one of MedImmune's drugs.
The Motley Fool July 30, 2007 Brian Orelli	Is Par Pharmaceutical Settling for Less? The generic drugmaker avoids going to court in some recent cases. Patent lawyers are the lifeblood of a generic drugmaker, and investors should want them to act as aggressively as possible so that Par can expand its product line.
The Motley Fool January 27, 2005 Stephen D. Simpson	AstraZeneca Shines, for Now The British-Swedish drug company has a great quarter, but the future looks dimmer.
Managed Care September 2006	Payers, Consumers Benefit as Patents Expire The generic drug market seems ready to explode, according to reports from IMS Health and the Generic Pharmaceuticals Association.
The Motley Fool June 1, 2007 Brian Lawler	The Generic Cracks Open for Pfizer Pfizer loses a patent case over its top compound. The larger takeaway from the Lipitor legal saga is that investors always need to be aware of the strength of a drug company's patents throughout the world.
The Motley Fool December 12, 2005 Rich Duprey	Patent? What Patent? Japanese drug firm Eisai sues Teva over a patented Alzheimer's treatment. Investors, take note.
The Motley Fool April 2, 2008 Brian Lawler	Bad Timing for AstraZeneca's Good Data AstraZeneca quietly reports a successful clinical study for its cholesterol-lowering lead drug.
The Motley Fool January 19, 2007 Brian Lawler	The Best Drug Stock for 2007: Endo Pharmaceuticals This drug-maker just might be a great investment at the current price.
The Motley Fool September 9, 2010 Jim Mueller	Today's Buy Opportunity: Teva Pharmaceutical Take advantage of this growing generic-drug maker.
The Motley Fool November 5, 2004 Roger Nusbaum	The Tale of Teva Generic drug companies like Teva may offer a smart way to own health care. However, the company's good fortune hit a bump when rival Andrx got pummeled with a bad earnings announcement, and Teva traded down in sympathy.
The Motley Fool August 13, 2010 Brian Orelli	Already a Slippery Slope for Eli Lilly The company gets a whiff of what its patent cliff might be like.
BusinessWeek January 31, 2005 Kerry Capell	No Relief For AstraZeneca More bad news about potential blockbusters weakens Europe's third-largest drugmaker. Analysts say the only thing keeping Astra's shares from going into free fall is the mounting speculation that GSK might make a play for the troubled drugmaker.
The Motley Fool April 14, 2008 Brian Orelli	Teva Gets What It Wants Teva persuades a court to order the FDA to award it a marketing exclusivity for generic Risperdal.
The Motley Fool February 9, 2004 Alyce Lomax	High Hopes for Andrx Are hopeful investors jumping the gun on the drug maker's generic prospects?